Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new?
Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What’s new?作者机构：Oncology Department Clínica Universitaria Universidad de Navarra Pamplona 31008 Spain Division of Oncology CIMA Spain Oncology Department Clínica Universitaria Universidad de Navarra Pamplona 31008 Spain Division of Oncology CIMA Spain
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2007年第13卷第44期
页 面：5877-5887页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Epidermal growth factor receptor inhibitors Cetuximab Panitumumab Erlotinib Gefitinib Metastatic colorectal cancer Tyrosine kinase inhibitors Monoclonal antibodies
摘 要：Colorectal cancer constitutes one of the most common malignancies and the second leading cause of death from cancer in the western world representing one million new cases and half a million deaths annually worldwide. The treatment of patients with metastatic colon cancer comprises different regimens of chemotherapeutic compounds （fluoropyrimidines, irinotecan and oxaliplatin） and new targeted therapies. Interestingly, most recent trials that attempt to expose patients to all five-drug classes （fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab and cetuximab） achieve an overall survival well over 2 years. In this review we will focus on the main epidermal growth factor receptor inhibitors demonstrating clinical benefit for colorectal cancer mainly cetuximab, panitumumab, erlotinib and gefltinib. We will also describe briefly the molecular steps that lie beneath them and the different clinical or molecular mechanisms that are reported for resistance and response.
维普期刊数据库